Literature DB >> 18782350

Selective induction of calcineurin activity and signaling by oligomeric amyloid beta.

Lindsay C Reese1, WenRu Zhang, Kelly T Dineley, Rakez Kayed, Giulio Taglialatela.   

Abstract

Alzheimer's disease (AD) is a terminal age-associated dementia characterized by early synaptic dysfunction and late neurodegeneration. Although the presence of plaques of fibrillar aggregates of the amyloid beta peptide (Abeta) is a signature of AD, evidence suggests that the preplaque small oligomeric Abeta promotes both synaptic dysfunction and neuronal death. We found that young Tg2576 transgenic mice, which accumulate Abeta and develop cognitive impairments prior to plaque deposition, have high central nervous system (CNS) activity of calcineurin (CaN), a phosphatase involved in negative regulation of memory function via inactivation of the transcription factor cAMP responsive element binding proteins (CREB), and display CaN-dependent memory deficits. These results thus suggested the involvement of prefibrillary forms of Abeta. To investigate this issue, we compared the effect of monomeric, oligomeric, and fibrillar Abeta on CaN activity, CaN-dependent pCREB and phosphorylated Bcl-2 Associated death Protein (pBAD) levels, and cell death in SY5Y cells and in rat brain slices, and determined the role of CaN on CREB phosphorylation in the CNS of Tg2576 mice. Our results show that oligomeric Abeta specifically induces CaN activity and promotes CaN-dependent CREB and Bcl-2 Asociated death Protein (BAD) dephosphorylation and cell death. Furthermore, Tg2576 mice display Abeta oligomers and reduced pCREB in the CNS, which is normalized by CaN inhibition. These findings suggest a role for CaN in mediating effects of oligomeric Abeta on neural cells. Because elevated CaN levels have been reported in the CNS of cognitively impaired aged rodents, our results further suggest that abnormal CaN hyperactivity may be a common event exacerbating the cognitive and neurodegenerative impact of oligomeric Abeta in the aging CNS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18782350      PMCID: PMC2954114          DOI: 10.1111/j.1474-9726.2008.00434.x

Source DB:  PubMed          Journal:  Aging Cell        ISSN: 1474-9718            Impact factor:   9.304


  49 in total

1.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

Review 2.  Calcineurin regulation of neuronal plasticity.

Authors:  Rachel D Groth; Robert L Dunbar; Paul G Mermelstein
Journal:  Biochem Biophys Res Commun       Date:  2003-11-28       Impact factor: 3.575

Review 3.  Alzheimer's disease is a synaptic failure.

Authors:  Dennis J Selkoe
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

4.  Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

Authors:  Salvatore Oddo; Antonella Caccamo; Jason D Shepherd; M Paul Murphy; Todd E Golde; Rakez Kayed; Raju Metherate; Mark P Mattson; Yama Akbari; Frank M LaFerla
Journal:  Neuron       Date:  2003-07-31       Impact factor: 17.173

5.  Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

Authors:  Hai-Wei Wang; Joseph F Pasternak; Helen Kuo; Helen Ristic; Mary P Lambert; Brett Chromy; Kirsten L Viola; William L Klein; W Blaine Stine; Grant A Krafft; Barbara L Trommer
Journal:  Brain Res       Date:  2002-01-11       Impact factor: 3.252

6.  Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse.

Authors:  Marcia N Gordon; Leigh A Holcomb; Paul T Jantzen; Giovanni DiCarlo; Donna Wilcock; Kristal W Boyett; Karen Connor; Jason Melachrino; James P O'Callaghan; Dave Morgan
Journal:  Exp Neurol       Date:  2002-02       Impact factor: 5.330

7.  Involvement of calcineurin in the neurotoxic effects induced by amyloid-beta and prion peptides.

Authors:  Paula Agostinho; Catarina Resende Oliveira
Journal:  Eur J Neurosci       Date:  2003-03       Impact factor: 3.386

Review 8.  Amyloid, presenilins, and Alzheimer's disease.

Authors:  Geert Van Gassen; Wim Annaert
Journal:  Neuroscientist       Date:  2003-04       Impact factor: 7.519

9.  Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus.

Authors:  Qi-Sheng Chen; Wei-Zheng Wei; Takeshi Shimahara; Cui-Wei Xie
Journal:  Neurobiol Learn Mem       Date:  2002-05       Impact factor: 2.877

10.  The similarities and diversities of signal pathways leading to consolidation of conditioning and consolidation of extinction of fear memory.

Authors:  Chih-Hung Lin; Shiu-Hwa Yeh; Hsin-Yi Lu; Po-Wu Gean
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

View more
  52 in total

1.  Reduction in neuronal L-type calcium channel activity in a double knock-in mouse model of Alzheimer's disease.

Authors:  Olivier Thibault; Tristano Pancani; Philip W Landfield; Christopher M Norris
Journal:  Biochim Biophys Acta       Date:  2012-01-10

Review 2.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

3.  α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.

Authors:  Zane S Martin; Volker Neugebauer; Kelly T Dineley; Rakez Kayed; Wenru Zhang; Lindsay C Reese; Giulio Taglialatela
Journal:  J Neurochem       Date:  2011-11-28       Impact factor: 5.372

4.  Dysregulated phosphorylation of Ca(2+) /calmodulin-dependent protein kinase II-α in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease.

Authors:  Lindsay C Reese; Fernanda Laezza; Randall Woltjer; Giulio Taglialatela
Journal:  J Neurochem       Date:  2011-09-28       Impact factor: 5.372

Review 5.  Regulatory Mechanisms of Endoplasmic Reticulum Resident IP3 Receptors.

Authors:  Syed Zahid Ali Shah; Deming Zhao; Sher Hayat Khan; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2015-04-10       Impact factor: 3.444

Review 6.  Dysregulation of neuronal calcium homeostasis in Alzheimer's disease - A therapeutic opportunity?

Authors:  Elena Popugaeva; Ekaterina Pchitskaya; Ilya Bezprozvanny
Journal:  Biochem Biophys Res Commun       Date:  2016-09-15       Impact factor: 3.575

7.  Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival.

Authors:  Abhisek Mukherjee; Diego Morales-Scheihing; Dennisse Gonzalez-Romero; Kristi Green; Giulio Taglialatela; Claudio Soto
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

8.  TNF-α contributes to caspase-3 independent apoptosis in neuroblastoma cells: role of NFAT.

Authors:  Susana Alvarez; Almudena Blanco; Manuel Fresno; Ma Ángeles Muñoz-Fernández
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

9.  Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease.

Authors:  Jennifer L Furman; Diana M Sama; John C Gant; Tina L Beckett; M Paul Murphy; Adam D Bachstetter; Linda J Van Eldik; Christopher M Norris
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

10.  S100a9 knockdown decreases the memory impairment and the neuropathology in Tg2576 mice, AD animal model.

Authors:  Tae-Young Ha; Keun-A Chang; Jeong a Kim; Hye-Sun Kim; Seonghan Kim; Young Hae Chong; Yoo-Hun Suh
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.